Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 1
1964 1
1965 3
1966 1
1967 1
1968 2
1970 3
1971 3
1972 1
1976 1
1978 2
1979 2
1980 2
1981 1
1982 4
1983 5
1984 2
1985 3
1986 3
1987 3
1988 4
1989 1
1990 2
1991 2
1992 6
1993 3
1994 5
1995 5
1996 12
1997 7
1998 8
1999 4
2000 6
2001 4
2002 8
2003 14
2004 7
2005 6
2006 10
2007 6
2008 8
2009 5
2010 8
2011 11
2012 9
2013 14
2014 14
2015 16
2016 16
2017 15
2018 19
2019 24
2020 20
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

325 results
Results by year
Filters applied: . Clear all
Page 1
Potential of hyperbaric oxygen in urological diseases.
Tanaka T, Minami A, Uchida J, Nakatani T. Tanaka T, et al. Among authors: uchida j. Int J Urol. 2019 Sep;26(9):860-867. doi: 10.1111/iju.14015. Epub 2019 May 13. Int J Urol. 2019. PMID: 31083787 Review.
Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice.
Nishide S, Uchida J, Matsunaga S, Tokudome K, Yamaguchi T, Kabei K, Moriya T, Miura K, Nakatani T, Tomita S. Nishide S, et al. Among authors: uchida j. J Pharmacol Sci. 2020 Jun;143(2):122-126. doi: 10.1016/j.jphs.2020.02.010. Epub 2020 Mar 3. J Pharmacol Sci. 2020. PMID: 32199747 Free article.
Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.
Kabei K, Tateishi Y, Shiota M, Osada-Oka M, Nishide S, Uchida J, Nakatani T, Matsunaga S, Yamaguchi T, Tomita S, Miura K. Kabei K, et al. Among authors: uchida j. J Pharmacol Sci. 2020 Mar;142(3):93-100. doi: 10.1016/j.jphs.2019.12.002. Epub 2019 Dec 6. J Pharmacol Sci. 2020. PMID: 31866051 Free article.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, Hirano K, Matsumoto H, Kominami R, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Kinoshita Y, Hara S, Kumagai T, Fujimoto D. Tamiya M, et al. Among authors: uchida j. Invest New Drugs. 2019 Dec;37(6):1266-1273. doi: 10.1007/s10637-019-00843-y. Epub 2019 Aug 7. Invest New Drugs. 2019. PMID: 31392549
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Hirano K, Matsumoto H, Kominami R, Tomii K, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Makio T, Hara S, Tamiya M. Hosoya K, et al. Among authors: uchida j. Clin Lung Cancer. 2020 Jul;21(4):e315-e328. doi: 10.1016/j.cllc.2020.01.003. Epub 2020 Feb 4. Clin Lung Cancer. 2020. PMID: 32113737
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H, Fukuda Y, Yokoyama T, Kominami R, Fujimoto D, Hosoya K, Suzuki H, Hirashima T, Kanazu M, Sawa N, Uchida J, Morita M, Makio T, Hara S, Kumagai T. Kawachi H, et al. Among authors: uchida j. Invest New Drugs. 2020 Feb;38(1):211-218. doi: 10.1007/s10637-019-00882-5. Epub 2019 Nov 30. Invest New Drugs. 2020. PMID: 31784866
325 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page